As a valid surrogate for insulin sensitivity that includes both laboratory and anthropometric measurements, METS-IR has been proposed as a tool to identify individuals at an elevated risk of developing T2DM, metabolic syndrome, and other cardiovascular diseases (CVDs) at an early age (16, 18). This evidence concerns the gene INS and type 2 diabetes mellitus.